China Shineway Pharmaceutical Group Limited (02877.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

Market Cap

HKD 6.24B

MomentumView details →

1D Return

+0.85%

YTD Return

−3.95%

RSI (14)

54.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

Market Cap

HKD 6.24B

RSI (14)

54.2

MomentumView details →

1D Return

+0.85%

YTD Return

−3.95%

ProfitabilityView details →

Gross Margin

72.44%

Net Margin

27.14%

EBITDA Margin

26.65%

ROE (TTM)

19.82%

ROA (TTM)

15.56%

Asset Turnover

0.56x

GrowthView details →

Revenue YoY

−31.44%

EPS YoY

−18.63%

FCF YoY

−48.00%

Revenue CAGR 3Y

−7.41%

EPS CAGR 3Y

+9.49%

EBITDA YoY

−28.38%

EarningsView details →

EPS (Actual)

HKD 0.72

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

1.28%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

4.32x

Quick Ratio

4.05x

Div Yield

7.35%

Div Rate

HKD 0.61

Div Growth 1Y

−3.56%

Financials snapshotView financials →

Revenue (TTM)

5.99B

Net Income (TTM)

1.63B

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

China Shineway Pharmaceutical declared a second interim dividend of RMB 0.80 per share for the six months ended June 2026, with total interim dividends of RMB 1.23 per share including the first interim dividend.9d ago

China Shineway Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 1.181 billion, down 28.5% year-on-year, and net profit of RMB 469 million, down 23.7% year-on-year.9d ago

Similar companies

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.09989.HK 昆药集团600422.SH 辰欣药业603367.SH 亚虹医药-U688176.SH Lantheus Holdings, Inc.LNTH 百克生物688276.SH Find similar companies →

Latest newsMore news →

China Shineway Pharmaceutical declared a second interim dividend of RMB 0.80 per share for the six months ended June 2026, with total interim dividends of RMB 1.23 per share including the first interim dividend.9d ago China Shineway Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 1.181 billion, down 28.5% year-on-year, and net profit of RMB 469 million, down 23.7% year-on-year.9d ago